<DOC>
	<DOCNO>NCT00393120</DOCNO>
	<brief_summary>This study evaluate safety , pharmacokinetics efficacy CCR5 antagonist INCB009471 HIV-1 infect patient antiretroviral therapy naïve , currently HAART regimen receive antiretroviral agent 3 month prior Screening visit . Subjects receive study medication ( INCB009471 ) admnistered orally placebo daily food 14 day . Clinical safety laboratory , 12-lead electrocardiogram , physical examination virologic assessment , include viral load , viral tropism CD4+ cell count determination perform Screening visit regularly schedule visit throughout study . A blood sample also obtain store potentially determine genotype CCR5 receptor . The primary objective : 1 . Assess safety tolerability 3 dos INCB009471 placebo administer orally , daily , monotherapy 14 day ; 2 . Determine pharmacokinetics 3 dos INCB009471 placebo administer orally , daily , monotherapy 14 day ; 3 . Evaluate anti-retroviral activity 3 dos INCB009471 placebo administer orally , daily , monotherapy 14 day</brief_summary>
	<brief_title>Safety/Effectiveness Oral Chemokine Coreceptor 5 ( CCR5 ) Antagonist INCB009471 R5-tropic HIV Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Asymptomatic HIV1 infect individual treatmen naïve ( ie less 2 week prior ARV exposure ) treatment experienced subject currently HAART receive ARVs 3 month prior Screening . Males 18 year 65 year age , utilize adequate contraceptive method . Post menopausal surgically sterile female 18 year 65 year age . Women childbearing potential , utilizing adequate contraceptive method . CD4lymphocyte count &gt; 350 cells/mm3 HIV1 RNA copies/ml &gt; 10,000 . HIV1 CCR5 tropic virus . CCR5 antagonist treatment naive . BMI &gt; 16 &lt; 32 kg/m2 . Have clinically significant finding screen evaluation , opinion Investigator would interfere subject 's ability comply protocol . Able comprehend willing sign Informed Consent Form . Current recent ( &lt; 30 day ) opportunistic infection . Presence CXCR4 dualtropic HIV1 virus Screening Baseline assessment . Subjects chronic renal insufficiency Personal history cardiac disease . History presence abnormal ECG . History unstable ischemic heart disease uncontrolled hypertension . History malignancy , exception cure basal cell squamous cell carcinoma skin . Subjects receive radiation therapy cytotoxic chemotherapeutic agent recover side effect . Current treatment treatment within 30 day 5 halflives another investigational medication current enrollment another investigational drug protocol . Subjects unstable medical condition ( ) , , opinion Investigator would compromise participation trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>HIV-infection</keyword>
	<keyword>viral load</keyword>
	<keyword>CCR5</keyword>
	<keyword>viral tropism</keyword>
	<keyword>HIV-1 infection</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>